CARVYKTI Continued Performance Reflects Growing Confidence In CAR-T Therapies For Multiple Myeloma Delveinsight
As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promis ...